JP Morgan Chase
OLMA icon

JP Morgan Chase’s Olema Pharmaceuticals OLMA Stock Holding History

JP Morgan Chase’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.92M Sell
142,762
-125,709
-47% -$2.8M ﹤0.01% 4132
2025
Q4 		$6.71M Buy
268,471
+238,340
+791% +$4.24M ﹤0.01% 3053
2025
Q3 		$295K Sell
30,131
-2,348
-7% -$14.1K ﹤0.01% 5307
2025
Q2 		$138K Sell
32,479
-254,454
-89% -$1.13M ﹤0.01% 5446
2025
Q1 		$1.08M Buy
286,933
+126,182
+78% +$635K ﹤0.01% 4291
2024
Q4 		$937K Sell
160,751
-20,281
-11% -$203K ﹤0.01% 4684
2024
Q3 		$2.16M Buy
181,032
+157,171
+659% +$2.01M ﹤0.01% 3948
2024
Q2 		$258K Buy
23,861
+976
+4% +$10.6K ﹤0.01% 5019
2024
Q1 		$259K Sell
22,885
-5,691
-20% -$73.4K ﹤0.01% 5200
2023
Q4 		$401K Buy
28,576
+10,203
+56% +$137K ﹤0.01% 4935
2023
Q3 		$227K Sell
18,373
-2,596
-12% -$26.5K ﹤0.01% 4994
2023
Q2 		$189K Buy
20,969
+19,775
+1,656% +$119K ﹤0.01% 5103
2023
Q1 		$4K Hold
1,194
– – ﹤0.01% 6299
2022
Q4 		$3K Sell
1,194
-281,081
-100% -$820K ﹤0.01% 6256
2022
Q3 		$779K Buy
282,275
+1,294
+0.5% +$5.49K ﹤0.01% 4185
2022
Q2 		$1.14M Buy
280,981
+252,181
+876% +$800K ﹤0.01% 3977
2022
Q1 		$122K Buy
28,800
+4,928
+21% +$27.2K ﹤0.01% 5414
2021
Q4 		$224K Buy
23,872
+6,354
+36% +$132K ﹤0.01% 5289
2021
Q3 		$483K Sell
17,518
-89,682
-84% -$2.42M ﹤0.01% 4751
2021
Q2 		$3M Buy
107,200
+6,890
+7% +$196K ﹤0.01% 3488
2021
Q1 		$3.33M Buy
100,310
+26,807
+36% +$1.15M ﹤0.01% 3309
2020
Q4 		$3.53M Buy
+73,503
New +$3.45M ﹤0.01% 3075

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

JP Morgan Chase's OLMA Position: Q1 2026 in Review

JP Morgan Chase reduced its Olema Pharmaceuticals (OLMA) stake by 47% in Q1 2026, selling an estimated $2.8M and leaving 142,762 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #4132.

JP Morgan Chase first reported a position in OLMA in Q4 2020 and has held it in 22 quarters since. The position peaked at $6.71M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • JP Morgan Chase held 142,762 shares of Olema Pharmaceuticals worth $1.92M as of Q1 2026.
  • JP Morgan Chase sold 125,709 Olema Pharmaceuticals shares in Q1 2026, an estimated $2.8M.
  • Olema Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4132 holding.
  • JP Morgan Chase first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • JP Morgan Chase's Olema Pharmaceuticals position peaked at $6.71M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.